Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Novo Nordisk has been losing big in the past year and is down over 66% from its peak in 2024. On the other hand, Eli Lilly ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

The drugmaker is a large and consistent client for Covington. The law firm has represented Novo Nordisk in several dozen ...

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its ...

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

Novo claims the defendants are steering patients toward compounded semaglutide that has not been approved by regulators; in ...

The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.